Sexual differentiation and reproductive development of female rat offspring after paternal exposure to the anti-tumor pharmaceutical cisplatin

Reprod Toxicol. 2016 Apr:60:112-22. doi: 10.1016/j.reprotox.2016.02.005. Epub 2016 Feb 8.

Abstract

Cisplatin (CP) is used to treat a number of cancers, including testicular cancer. Studies indicate that CP-treatment can impair spermatogenesis in humans and rodents by germ cell DNA binding, through different modes of action. CP-paternal exposure resulted in adverse effects in F1 male offspring. In this study, F1 female offspring was assessed for reproductive development after CP-paternal exposure. Peri-pubertal male rats, treated with 1mg/Kg/day of CP or vehicle for 3 weeks, were mated with unexposed females. F1 female offspring of CP-treated fathers showed a decrease in fetal ovary germ cells, in estrous cycle length and FSH levels, and an increase in the percentage of antral follicles in adults. Based on our previous results and the findings of the present work we concluded that CP-paternal exposure leads to adverse effects on rat male and female reproductive development, raising concern, in humans, for children born to men exposed to CP.

Keywords: Cisplatin; Female rat; Paternal exposure; Reproductive toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / toxicity*
  • Cisplatin / toxicity*
  • Estrous Cycle / drug effects
  • Female
  • Fertility / drug effects
  • Follicle Stimulating Hormone / blood
  • Germ Cells / drug effects
  • Male
  • Ovary / drug effects
  • Paternal Exposure*
  • Pregnancy
  • Prenatal Exposure Delayed Effects*
  • Rats, Wistar
  • Sex Differentiation / drug effects*
  • Sexual Behavior, Animal / drug effects

Substances

  • Antineoplastic Agents
  • Follicle Stimulating Hormone
  • Cisplatin